---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031340"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:16:31.271855+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences reports Q2 2024 net loss of $1.7M; prioritizes EB-003 as lead candidate

## Summary
- Net loss of $1.7M ($0.23/share) vs $6.4M loss in Q2 2023; cash on hand $3.5M.
- Prioritized EB-003, a non-hallucinogenic neuroplastogenic molecule, as lead development candidate.
- Preclinical data confirms oral bioavailability and brain exposure of EB-003; IND filing expected Q3 2025.
- Signed licensing agreement with Aries Science & Technology for radiation dermatitis product; non-binding term sheets for joint disease and cancer treatments.

## SEC filing metadata
- accession: 0001493152-24-031340
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224031340/0001493152-24-031340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224031340/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031340
- JSON: https://secwatch.observer/filing/0001493152-24-031340.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031340.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.